BenevolentAI Goes Public In Europe’s Largest SPAC
Valued at €1.5bn
Executive Summary
The UK computational medicines specialist is listing on the Euronext Amsterdam after linking up with healthcare-focused special purpose acquisition corporation Odyssey which is advised by former Sanofi CEO Olivier Brandicourt.
You may also be interested in...
BenevolentAI Slashes Jobs And Drug Programs
The UK firm, which uses artificial intelligence to discover and develop drugs, is hoping to save £45m by halving its workforce and trimming its pipeline.
BenevolentAI Atopic Dermatitis Drug Fails To Deliver
The UK artificial intelligence drug development expert has reported disappointing findings from a Phase II trial of lead candidate BEN-2293 in atopic dermatitis.
The Secret Sauce To BenevolentAI’s Ongoing Success
In a crowded AI-driven drug development sector, BenevolentAI stands out with its broad pipeline of drug candidates, deep pockets, and a growing partnership with AstraZeneca. Ivan Griffin, company co-founder and chief operating officer spoke with In Vivo about the formula behind the company’s successes.